Savara Pharmaceuticals has discontinued its clinical program of the inhaled antibiotic formulation Apulmiq (ciprofloxacin) for the treatment of non-cystic fibrosis bronchiectasis (NCFB). This decision comes with the announcement of Savara‘s ... Read more